United Kingdom Archives

Interview 28 Sep 2017

Ethical Drug Development can Start with Charity Investors: A Conversation

As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity investors. In August, a story emerged that Novartis CEO Joe Jimenez not only responded to a patient’s letter but met with him soon thereafter to […]

September 28, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 27 Sep 2017

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of […]

September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Sep 2017

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at both hematological cancers and solid tumors. The Series C fundraising of $80M (€68M) is added to £70M (€80M) made in Series A […]

September 26, 2017 - 3 minutesmins - By Alex Dale

More News! 20 Sep 2017

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work on a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets, on which Glythera will have the option […]

September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Sep 2017

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

A British-American collaboration’s once-daily triple therapy inhaler has been approved for use by appropriate COPD patients in the US. A new triple therapy inhaler for chronic obstructive pulmonary disease (COPD), Trelegy Ellipta, has been developed by British giant GSK in collaboration with Innoviva in the US. The inhaler is targeted at patients who are struggling with airflow […]

September 20, 2017 - 2 minutesmins - By Alex Dale

derek jones babraham bioscience technologies incubator

Interview 20 Sep 2017

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

Derek Jones is at the helm of Babraham Bioscience Technologies. I caught up with him to talk about strategies for biotech startups. Confusion is common when it comes to navigating the various organizing entities of Babraham, a life science campus just a few kilometers southeast of Cambridge. It’s famously home to a number of standout […]

September 20, 2017 - 9 minutesmins - By Evelyn Warner

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […]

September 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […]

September 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 15 Sep 2017

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Levicept’s Phase I study will test their new pain relief candidate’s safety and tolerability in healthy individuals and osteoarthritis patients. Levicept, based in Sandwich, UK, focuses on the development of its pain relief candidate, LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc). The Phase I study is the company’s maiden voyage into the clinic, and it will test the […]

September 15, 2017 - 3 minutesmins - By Alex Dale

More News! 14 Sep 2017

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

Scientists in the UK and US have identified how in-fighting between bacteria could provide a new treatment for hospital-acquired infections. Clostridium difficile is a common cause of hospital-acquired infections, which kill almost 4,000 people in Europe each year. Scientists at the University of Sheffield, the University of Glasgow, and California-based biotech AvidBiotics Corp have discovered that C. difficile uses nanomolecular […]

September 14, 2017 - 2 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

Summit Therapeutics has been awarded the Barda Contract worth up to $62M (€52M) to continue to the development of a new antibiotic for hospital-acquired infections. Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to […]

September 12, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Ethical Drug Development can Start with Charity Investors: A Conversation

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!